Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20645 (
mannose-6-phosphate receptor
)
320
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Neuronal ceroid lipofuscinoses (NCLs) represent a group of children's inherited neurodegenerative disorders caused by mutations in at least eight different genes. Mutations in the
CLN5
gene result in the Finnish variant late infantile NCL characterized by gradual loss of vision, epileptic seizures, and mental deterioration. The
CLN5
gene encodes a lysosomal glycoprotein of unidentified function. In this study, we have used both transient and stable expression systems for the characterization of
CLN5
, focusing on the localization, processing, and intracellular trafficking. We show that
CLN5
is proteolytically cleaved, and that the mature polypeptide is transported to the lysosomes. Our data provide the first evidence that soluble
CLN5
protein can also undergo
mannose-6-phosphate receptor
-independent trafficking to the lysosomes. We studied the localization and maturation of the
CLN5
carrying the previously uncharacterized vLINCL disease causing mutations in HeLa cells. All analyzed disease mutations disturb the lysosomal trafficking of the mutated
CLN5
proteins. The level of lysosomal targeting does not correlate, however, to disease onset, indicating that
CLN5
may also function outside lysosomes. This study furthers our understanding of the basic properties of the
CLN5
protein, necessary for the characterization of the consequences of disease mutations and for the planning of future therapies for vLINCL.
...
PMID:The neuronal ceroid lipofuscinosis protein CLN5: new insights into cellular maturation, transport, and consequences of mutations. 2005 65